Skip to main content
. 2023 Jun 26;183(8):832–838. doi: 10.1001/jamainternmed.2023.2442

Table 3. Mortality Analysis in 17 726 Individuals With Nonfunctional Adrenal Adenomas Compared With 124 366 Controls, Unadjusted and Adjusted to Age, Sex, and Possible Confoundersa.

Characteristic Cases Controls Hazard ratio (95% CI) P value Adjusted hazard ratio (95% CI) P value
Overall total mortalityb 3719 19 343 1.43 (1.38-1.48) <.001 1.21 (1.16-1.26) <.001
Mortality due to cancer 851 3719 1.63 (1.51-1.76) <.001 1.54 (1.42-1.67) <.001
Mortality due to CV diseases 1212 6369 1.43 (1.34-1.52) <.001 1.21 (1.13-1.29) <.001
Men 1522 9365 1.35 (1.28-1.43) <.001 1.19 (1.11-1.26) <.001
Women 2197 9978 1.52 (1.45-1.59) <.001 1.22 (1.15-1.28) <.001
Age <65 y 750 2350 2.26 (2.07-2.46) <.001 1.44 (1.31-1.58) <.001
Age >65 y 2969 16 993 1.4 (1.34-1.45) <.001 1.15 (1.1-1.2) <.001
Adrenalectomy 352 124 366 0.74 (0.56-0.97) .03 0.95 (0.72-1.24) .69
No adrenalectomy 17 374 124 366 1.45 (1.4-1.5) <.001 1.21 (1.16-1.26) <.001

Abbreviation: CV, cardiovascular.

a

All cases with cancer discovered within the first 3 months after the diagnosis of the nonfunctional adrenal adenoma have been excluded.

b

Overall follow-up period up to 16 years.